Analysis of phospholipid molecular species in brains from patients with infantile and juvenile neuronal-ceroid lipofuscinosis using liquid chromatography-electrospray ionization mass spectrometry.
Phospholipids (PL) in cerebral cortex from patients with infantile (INCL or CLN1) and juvenile (JNCL or CLN3) forms of neuronal ceroid-lipofuscinosis (NCL) and controls were analysed by normal phase HPLC and on-line electrospray ionization ion-trap mass spectrometric detection (LC-ESI-MS). The method provided quantitative data on numerous molecular species of different PL classes, which are not achieved by using the conventional chromatographic methods. Compared with the controls, the INCL brains contained proportionally more phosphatidylcholine (PC), and less phosphatidylethanolamine (PE) and phosphatidylserine (PS). Different molecular species of PC, PE, PS, phosphatidylinositol and sphingomyelin were quantified using multiple internal PL standards that differed in fatty acyl chain length and thus allowed correction for chain length dependency of instrument response. In INCL cortex, which had lost 65% of the normal PL content, the proportions of polyunsaturated molecular species, especially the PS and PE that contained docosahexaenoic acid (22:6n-3), were dramatically decreased. The membranes may have adapted to this alteration by increasing the proportions of PL molecules substituted with monounsaturated and short-chain fatty acids. Lysobisphosphatidic acid was highly elevated in the INCL brain and consisted mostly of polyunsaturated species. It is possible that changes in the composition of PL membranes accelerate progression of INCL by altering signalling and membrane trafficking in neurons.
Käkelä
Reijo
R
Institute of Biomedicine/Biochemistry, Biomedicum Helsinki, University of Helsinki, Haartmaninkatu 8, 00014 Helsinki, Finland.
Somerharju
Pentti
P
Tyynelä
Jaana
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D001923:Brain Chemistry; D002540:Cerebral Cortex / Q000737:chemistry* / Q000378:metabolism*; D002648:Child; D002851:Chromatography, High Pressure Liquid; D018450:Disease Progression; D006801:Humans; D008246:Lysophospholipids / Q000032:analysis; D008297:Male; D050178:Monoglycerides; D009472:Neuronal Ceroid-Lipofuscinoses / Q000378:metabolism*; D010713:Phosphatidylcholines / Q000032:analysis; D010714:Phosphatidylethanolamines / Q000032:analysis; D010715:Phosphatidylglycerols / Q000032:analysis; D010716:Phosphatidylinositols / Q000032:analysis; D010718:Phosphatidylserines / Q000032:analysis; D010743:Phospholipids / Q000032:analysis*; D012016:Reference Values; D021241:Spectrometry, Mass, Electrospray Ionization; D013109:Sphingomyelins / Q000032:analysis
D008246:Lysophospholipids; D050178:Monoglycerides; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D010715:Phosphatidylglycerols; D010716:Phosphatidylinositols; D010718:Phosphatidylserines; D010743:Phospholipids; D013109:Sphingomyelins; C012786:bis(monoacylglyceryl)phosphate